


Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
		Application Number	10/751,274		
		Filing Date	December 31, 2003		
		First Named Inventor	KOZLOWSKI, Antoni		
		Group Art Unit	1713		
		Confirmation No.	7476		
		Examiner Name	Roberto RABAGO		
		Attorney Docket Number	6800-0063 (SHE0063)		
Sheet	1	of	1		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	(if known)		

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>5</sup>
		Office <sup>3</sup>	Number <sup>4</sup> Code	Kind			
<i>W</i>	B79	WO	03/000278	A1	Kyowa Hakko Kogyo Co., Ltd	01-03-2003	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>

<sup>1</sup> Unique citation designation number.

<sup>1</sup> Applicant is to place a check mark here if English language Translation attached.

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number.

<sup>2</sup> See attached Kinds of U.S. Patent Documents.

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box →

+



PTO/SB/08A (08-0)

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		Application Number	10/751,274
		Filing Date	December 31, 2003
		Confirmation Number	7476
		First Named Inventor	Kozlowski <i>et al.</i>
		Group Art Unit	1713
		Examiner Name	Rabago, Roberto
Sheet 1 of 1	Attorney Docket Number	41714-8016.US00 (SHE0063.00)	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
PK	1.	Enzon Pharmaceuticals Catalog, "Macromolecular Engineering Technologies," pp: 1-14 (2004).	
PK	2.	Nektar Molecule Engineering Catalog, "Polyethylene Glycol and Derivatives for Advanced PEGylation," pp: 1-21 (2003).	
PK	3.	Nektar Advanced PEGylation Catalog, "Polyethylene Glycol and Derivatives for Advanced PEGylation," pp: 1-24 (2004).	
PK	4.	Nektar Advanced PEGylation Catalog, "Polyethylene Glycol and Derivatives for Advanced PEGylation," pp: 1-30 (2005-2006).	
PK	5.	NOF Corporation Catalog, "Peg Derivatives, Phospholipid and Drug Delivery Materials for Pharmaceuticals," 1: pp: 2-46 (2003).	
PK	6.	Polypure Products Catalog, April 2005.	
PK	7.	Quanta Biodesign Catalog, "Labeling, Modification and Crosslinking Reagents Incorporating our Unique Monodispersed dPEG™ Technology," pp: 1-38, March 12, 2004.	
PK	8.	Quanta Biodesign Catalog, "Labeling, Derivatization and Crosslinking Reagents for Biological and Related Materials with dPEG," pp: 1-31, November 5, 2004.	
PK	9.	Quanta Biodesign Product Catalog, "Leading Innovator, Producer and Provider of Monodisperse Discrete PEG (dPEG) Derivatives," pp: 1-51, November 17, 2005.	
PK	10.	Shearwater Polymers, Inc., Catalog, "Functionalized Biocompatible Polymers for Research: Polyethylene Glycol and Derivatives," pp: 2-49 (March, 1995).	
PK	11.	Shearwater Polymers, Inc., Catalog, "Functionalized Biocompatible Polymers for Research and Pharmaceuticals: Polyethylene Glycol and Derivatives," pp: 2-53 (1997-1998).	
PK	12.	Shearwater Polymers, Inc., Catalog, "Functionalized Biocompatible Polymers for Research and Pharmaceuticals: Polyethylene Glycol and Derivatives," pp: 2-50 (2000).	

Examiner Signature	<i>Roberto Rabago</i>	Date Considered	5/14/07
--------------------	-----------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number.

<sup>1</sup> Applicant is to place a check mark here if English language Translation attached.